Albendazole + Ivermectin + Praziquantel

The combination of albendazole, ivermectin, and praziquantel is an antiparasitic treatment used primarily for controlling multiple helminth infections simultaneously. This triple therapy has been studied and implemented in areas where lymphatic filariasis, soil-transmitted helminthiasis, onchocerciasis, and schistosomiasis are co-endemic[1][2]. ## Mechanism of Action Each component in this combination targets different parasites through distinct mechanisms: - **Albendazole** works by preventing worms from absorbing glucose, causing them to lose energy and die. It's effective against soil-transmitted helminths[3]. - **Ivermectin** binds to muscle and nerve cells of parasites, causing paralysis and death. It's particularly effective against filarial worms that cause lymphatic filariasis and onchocerciasis[3]. - **Praziquantel** is active against schistosomiasis and other trematode infections[1][6]. ## Safety Profile Studies have shown that co-administration of these three drugs is generally safe in areas where the target diseases are endemic and where previous rounds of treatment with one or two of these drugs have been implemented[1]. A pilot intervention in Zanzibar, Tanzania, followed by a countrywide implementation covering approximately 700,000 individuals, demonstrated that side effects were mild and self-limiting[1]. Common side effects may include: - Digestive effects (diarrhea, vomiting, abdominal pain) - Neurological effects (migraine, dizziness) - Increased liver enzymes - Joint pain - Fever - Headache - Hair loss - Fatigue - Vertigo[3][4] ## Administration Guidelines The administration of this triple therapy typically follows specific protocols: 1. In some cases, the drugs are administered sequentially, with praziquantel given first, followed by albendazole and ivermectin, to reduce the risk of adverse events in persons with high parasite loads[6]. 2. In areas where previous rounds of mass anti-helminth treatment have occurred, all three drugs can be co-administered as this has been shown to be well-tolerated[6]. 3. Treatment is usually administered as directly observed therapy, with dosing often based on height rather than weight for ease of field implementation[5][6]. ## Contraindications This combination therapy should not be administered to: - Children under specific age/height thresholds (varies by drug) - Pregnant women - Women who have delivered less than one week ago - Seriously ill individuals[5][6] Specific contraindications by drug: - Albendazole: Not for children under 1 year - Ivermectin: Not for children weighing less than 15 kg or measuring less than 90 cm - Praziquantel: Not established as safe for children under 4 years or less than 94 cm in height[6] This triple therapy represents an important tool in integrated approaches to controlling multiple neglected tropical diseases simultaneously, potentially improving cost-effectiveness and logistical efficiency of mass drug administration programs.

Other names

Triple therapy